Subcutaneous (SC) injections are given at home — they're convenient and less expensive. Intravenous (IV) infusions are given in a clinic — they're more invasive but allow for higher doses and faster action. The TNF alpha inhibitors market research study shows that SC holds the largest share, but IV is the fastest‑growing, especially for acute flares or for patients who can't self‑inject (e.g., severe arthritis).

What's the difference? SC drugs (adalimumab, etanercept) are given weekly or biweekly. IV drugs (infliximab) are given every 4‑8 weeks in a clinic. The TNF alpha inhibitors market trends highlight that the fastest‑growing patient demographic is pediatric, as more children with juvenile idiopathic arthritis are treated with TNF inhibitors.

But IV infusions require travel, time, and IV access — a problem for patients with difficult veins.

The bottom line: choose SC for convenience, IV for potency. Talk to your doctor about your lifestyle and disease severity.